Cooperative platform (facsnanort-qpcr): contribution to the successful management of patients with mrd leukemia

Abstract

t(9;22) Ph translocation is a chromosome abnormality recurrent in human chronic myelogenous leukemia (CML) and cases of childhood acute lymphoblastic leukemia (ALL). Ph is a marker of adverse prognosis significant with remission more frequent and earlier and lower percentage of overall survival. If there are less than 5% blasts in a bone marrow sample, the patient is in "clinical remission". In the light of sensitivity current controls molecular (10-6) are an important role in therapy, although this depends on the amount of cells analyzed. Our goal is to improve the sensitivity by proposing a platforms combination, which allow MRD evaluation with only 10 cells. Flow cytometry sorting (multiparameter immunological detection), nano-PCR (RNA isolation and RT) and qPCR (diagnostic confirmation). The molecular remission has many more probability to be lasting that the cytogenetic remission, both before and after the transplant. We consider this technique as an important step forward towards performed diagnosis, monitoring treatment responses, and identification of relapse in Leukemia patients.